Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

C3993

Carvedilol

≥98% (HPLC), β-adrenergic blocker, solid

Sinónimos:

1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol, BM-14190

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C24H26N2O4
Número CAS:
72956-09-3
Peso molecular:
406.47
UNSPSC Code:
12352200
PubChem Substance ID:
329775050
NACRES:
NA.77
MDL number:
MFCD00864692
Assay:
≥98% (HPLC)
Form:
solid
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Carvedilol, ≥98% (HPLC), solid

assay

≥98% (HPLC)

form

solid

color

white to off-white

solubility

DMSO: >20 mg/mL

originator

GlaxoSmithKline

SMILES string

OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC

InChI

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

InChI key

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRB1(153), ADRB2(154), ADRB3(155)

Application

Carvedilol has been used:
  • as a β blocker to determine its effect on hypoxia inducible factor (HIF)-mediated erythropoiesis under hypoxia in vivo
  • as a βAR antagonist for inhibition of bARs
  • as a β-blocker to examine airway mechanics in fungus-challenged mice

Biochem/physiol Actions

Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity.
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Warning

hcodes

H373,H411

Hazard Classifications

Aquatic Chronic 2 - STOT RE 2

target_organs

Liver,spleen,Uterus (including cervix),Adrenal gland

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000531544
0000531544
0000494293
0000494293
0000396235

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Long-acting beta agonists enhance allergic airway disease
Knight JM, et al.
Testing, 10(11), e0142212-e0142212 (2015)
Hypoxia sensing through beta-adrenergic receptors
Cheong HI, et al.
JCI insight, 1(21) (2016)
V J Thanawala et al.
British journal of pharmacology, 172(20), 4833-4846 (2015-07-28)
Our previous studies have shown the β2 -adrenoceptor and its endogenous ligand, adrenaline, are required for development of the asthma phenotype in murine asthma models. Chronic administration of some, but not other, β-blockers attenuated the asthma phenotype and led us
Ver todos los artículos relacionados